<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00105170</url>
  </required_header>
  <id_info>
    <org_study_id>202-01</org_study_id>
    <nct_id>NCT00105170</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of hCBE-11, a Humanized Monoclonal Antibody, in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <brief_summary>
    <textblock>
      This is a Phase I, open-label, dose-escalation study on subjects with advanced solid tumors.&#xD;
      This is the first study of hCBE-11 in humans and is designed to determine the safety and how&#xD;
      well patients tolerate this investigational drug. The study duration is two years with&#xD;
      treatment visits occurring weekly for either 4 or 8 weeks, follow-up for 8 weeks and&#xD;
      long-term follow-up contact every 3 months thereafter.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of hCBE-11 in advanced solid tumors</measure>
    <time_frame>up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To define the recommended Phase II dose of hCBE-11</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">13</enrollment>
  <condition>Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hCBE-11</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Relapsed or refractory solid tumors not curable with standard therapy.&#xD;
&#xD;
          -  At least one measurable lesion&#xD;
&#xD;
          -  ECOG Performance Status less than or equal to 2&#xD;
&#xD;
          -  Acceptable hematologic status&#xD;
&#xD;
          -  Albumin greater than or equal to 2.5 g/dL&#xD;
&#xD;
          -  Normal calculated glomerular filtration rate (GFR)&#xD;
&#xD;
          -  Acceptable liver function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled cardiac disease, angina, congestive heart failure, or myocardial&#xD;
             infarction within 6 months prior to Study Day&#xD;
&#xD;
          -  Known history of hepatitis B or C, or HIV infection&#xD;
&#xD;
          -  Clinically significant effusions, including pericardial, pleural, and ascites&#xD;
&#xD;
          -  Serious non-malignant disease&#xD;
&#xD;
          -  Central nervous system (CNS) metastatic involvement except where the disease has been&#xD;
             successfully treated&#xD;
&#xD;
          -  Investigational therapies within 4 weeks of Study Day 1&#xD;
&#xD;
          -  Radiation therapy of tumors to be followed for this study&#xD;
&#xD;
          -  Chemotherapy, biologic therapy, or major surgery other than diagnostic within 4 weeks&#xD;
             prior to Study Day 1&#xD;
&#xD;
          -  Current Grade 3 or 4 neurological toxicity&#xD;
&#xD;
          -  Concurrent anti-neoplastic therapy and/or steroids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>March 8, 2005</study_first_submitted>
  <study_first_submitted_qc>March 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2005</study_first_posted>
  <last_update_submitted>April 25, 2013</last_update_submitted>
  <last_update_submitted_qc>April 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Monoclonal antibody</keyword>
  <keyword>Advanced solid tumors</keyword>
  <keyword>Tumors</keyword>
  <keyword>hCBE-11</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

